Total Payments
$296,275
2024 Payments
$182,991
Companies
28
Transactions
154
Medicare Patients
1,143
Medicare Billing
$102,466
Payment Breakdown by Category
Research$289,569 (97.7%)
Food & Beverage$2,696 (0.9%)
Other$2,500 (0.8%)
Travel$1,208 (0.4%)
Education$301.99 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $289,569 | 7 | 97.7% |
| Food and Beverage | $2,696 | 138 | 0.9% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2,500 | 1 | 0.8% |
| Travel and Lodging | $1,208 | 2 | 0.4% |
| Education | $301.99 | 6 | 0.1% |
Payments by Type
Research
$289,569
7 transactions
General
$6,707
147 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Nielsen BioSciences, Inc. | $182,769 | 1 | $0 (2024) |
| Bausch Health US, LLC | $104,800 | 5 | $0 (2019) |
| ParaPRO, LLC | $2,500 | 1 | $0 (2017) |
| Valeant Pharmaceuticals North America LLC | $2,000 | 1 | $0 (2017) |
| PFIZER INC. | $1,679 | 13 | $0 (2019) |
| ABBVIE INC. | $472.79 | 29 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $240.16 | 14 | $0 (2024) |
| Janssen Biotech, Inc. | $225.74 | 6 | $0 (2020) |
| Lilly USA, LLC | $223.56 | 16 | $0 (2020) |
| Amgen Inc. | $206.28 | 12 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $182,991 | 13 | Nielsen BioSciences, Inc. ($182,769) |
| 2023 | $184.24 | 10 | AbbVie Inc. ($87.59) |
| 2022 | $149.49 | 9 | Sun Pharmaceutical Industries Inc. ($46.00) |
| 2021 | $47.39 | 3 | AbbVie Inc. ($30.71) |
| 2020 | $148.63 | 4 | Janssen Biotech, Inc. ($99.00) |
| 2019 | $3,775 | 33 | Bausch Health US, LLC ($3,200) |
| 2018 | $103,990 | 49 | Bausch Health US, LLC ($101,600) |
| 2017 | $4,990 | 33 | ParaPRO, LLC ($2,500) |
All Payment Transactions
154 individual payment records from CMS Open Payments — Page 1 of 7
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/05/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $14.73 | General |
| Category: Dermatology | ||||||
| 11/30/2024 | Nielsen BioSciences, Inc. | Candin (Biological) | — | Cash or cash equivalent | $182,768.50 | Research |
| Study: CFW-3A • Category: Immunotherapy | ||||||
| 11/04/2024 | SUN PHARMACEUTICAL INDUSTRIES INC. | ILUMYA (Biological) | Food and Beverage | In-kind items and services | $13.14 | General |
| Category: Dermatology | ||||||
| 10/07/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $16.80 | General |
| Category: Dermatology | ||||||
| 09/30/2024 | SUN PHARMACEUTICAL INDUSTRIES INC. | ILUMYA (Biological) | Food and Beverage | In-kind items and services | $13.63 | General |
| Category: Dermatology | ||||||
| 06/04/2024 | GENZYME CORPORATION | DUPIXENT (Biological), DUPIXENT | Food and Beverage | In-kind items and services | $20.94 | General |
| Category: Immunology | ||||||
| 05/01/2024 | SUN PHARMACEUTICAL INDUSTRIES INC. | ILUMYA (Biological) | Food and Beverage | In-kind items and services | $28.16 | General |
| Category: Dermatology | ||||||
| 04/29/2024 | GENZYME CORPORATION | DUPIXENT (Biological), DUPIXENT | Food and Beverage | In-kind items and services | $24.53 | General |
| Category: Immunology | ||||||
| 04/18/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $16.10 | General |
| Category: Dermatology | ||||||
| 03/18/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $18.09 | General |
| Category: IMMUNOLOGY | ||||||
| 02/28/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $19.33 | General |
| Category: Dermatology | ||||||
| 01/25/2024 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $14.10 | General |
| Category: Inflammation | ||||||
| 01/09/2024 | SUN PHARMACEUTICAL INDUSTRIES INC. | ILUMYA (Biological) | Food and Beverage | In-kind items and services | $22.66 | General |
| Category: Dermatology | ||||||
| 12/12/2023 | Sun Pharmaceutical Industries Inc. | Odomzo (Drug), BLU-U | Food and Beverage | In-kind items and services | $16.78 | General |
| Category: Oncology | ||||||
| 12/04/2023 | AbbVie Inc. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $18.07 | General |
| Category: IMMUNOLOGY | ||||||
| 11/13/2023 | AbbVie Inc. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $19.92 | General |
| Category: IMMUNOLOGY | ||||||
| 11/01/2023 | LEO Pharma Inc. | — | Education | In-kind items and services | $25.00 | General |
| 11/01/2023 | LEO Pharma Inc. | — | Education | In-kind items and services | $25.00 | General |
| 10/30/2023 | AbbVie Inc. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $13.58 | General |
| Category: IMMUNOLOGY | ||||||
| 07/18/2023 | AbbVie Inc. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $19.62 | General |
| Category: IMMUNOLOGY | ||||||
| 04/25/2023 | AbbVie Inc. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $16.40 | General |
| Category: IMMUNOLOGY | ||||||
| 04/11/2023 | Kerecis Limited | Kerecis Omega3 SurgiClose (Device), Kerecis Omega3 GraftGuide, Kerecis Omega3 SurgiClose | Food and Beverage | Cash or cash equivalent | $13.21 | General |
| Category: Wound Care | ||||||
| 04/04/2023 | Fresenius Kabi USA, LLC | — | Food and Beverage | In-kind items and services | $16.66 | General |
| 12/21/2022 | Sun Pharmaceutical Industries Inc. | Odomzo (Drug), BLU-U | Food and Beverage | In-kind items and services | $13.41 | General |
| Category: Oncology | ||||||
| 11/02/2022 | Paratek Pharmaceuticals, Inc. | NUZYRA (Drug) | Food and Beverage | In-kind items and services | $15.93 | General |
| Category: ANTIBIOTIC | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| CFW-3A | Nielsen BioSciences, Inc. | $182,769 | 1 |
| A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLECONTROLLED, PARALLEL-GROUP, CLINICAL STUDY COMPARING THE EFFICACY AND SAFETY OF IDP-126 GEL IN THE TREATMENT OF ACNE VULGARIS | Bausch Health US, LLC | $104,800 | 5 |
| A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLECONTROLLED, PARALLEL-GROUP, CLINICAL STUDY COMPARING THE EFFICACY AND SAFETY OF IDP-126 GEL IN THE TREATMENT OF ACNE VULGARIS | Valeant Pharmaceuticals North America LLC | $2,000 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2020 | 15 | 1,143 | 1,727 | $182,606 | $102,466 |
Total Patients
1,143
Total Services
1,727
Medicare Billing
$102,466
Procedure Codes
15
All Medicare Procedures & Services
15 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 17311 | Removal and microscopic examination of growth of the head, neck, hands, feet, or genitals (first stage, up to 5 tissue blocks) | Office | 2020 | 54 | 75 | $47,060 | $29,208 | 62.1% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 287 | 332 | $34,816 | $17,351 | 49.8% |
| 17313 | Removal and microscopic examination of growth of the trunk, arms, or legs (first stage, up to 5 tissue blocks) | Office | 2020 | 27 | 29 | $17,106 | $11,254 | 65.8% |
| 17312 | Removal and microscopic examination of growth of the head, neck, hands, feet, or genitals | Office | 2020 | 24 | 31 | $11,540 | $8,662 | 75.1% |
| 17000 | Destruction of skin growth | Office | 2020 | 192 | 224 | $14,098 | $6,932 | 49.2% |
| 11102 | Tangential biopsy of single skin lesion | Office | 2020 | 113 | 130 | $12,048 | $6,858 | 56.9% |
| 17110 | Destruction of up to 14 skin growths | Office | 2020 | 95 | 107 | $11,054 | $6,473 | 58.6% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 107 | 123 | $8,632 | $5,151 | 59.7% |
| 13132 | Repair of wound (2.6 to 7.5 centimeters) of forehead, cheeks, chin, mouth, neck, underarms, genitals, hands, and/or feet | Facility | 2020 | 28 | 29 | $12,876 | $3,572 | 27.7% |
| 17003 | Destruction of 2-14 skin growths | Office | 2020 | 127 | 538 | $3,260 | $2,107 | 64.6% |
| 13121 | Repair of wound (2.6 to 7.5 centimeters) of scalp, arms, and/or legs | Facility | 2020 | 13 | 13 | $5,174 | $1,771 | 34.2% |
| 99203 | New patient office or other outpatient visit, typically 30 minutes | Office | 2020 | 22 | 22 | $2,346 | $1,381 | 58.8% |
| 11103 | Tangential biopsy of additional skin lesion | Office | 2020 | 17 | 26 | $1,300 | $979.24 | 75.3% |
| 11900 | Injection of up to 7 skin growths | Office | 2020 | 20 | 24 | $1,248 | $739.07 | 59.2% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2020 | 17 | 24 | $48.00 | $28.92 | 60.3% |
About Dr. Dowling Stough, MD
Dr. Dowling Stough, MD is a Dermatology healthcare provider based in Hot Springs, Arkansas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/29/2005. The National Provider Identifier (NPI) number assigned to this provider is 1831199884.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Dowling Stough, MD has received a total of $296,275 in payments from pharmaceutical and medical device companies, with $182,991 received in 2024. These payments were reported across 154 transactions from 28 companies. The most common payment nature is "" ($289,569).
As a Medicare-enrolled provider, Stough has provided services to 1,143 Medicare beneficiaries, totaling 1,727 services with total Medicare billing of $102,466. Data is available for 1 year (2020–2020), covering 15 distinct procedure/service records.
Ad
Practice Information
- Specialty Dermatology
- Location Hot Springs, AR
- Active Since 07/29/2005
- Last Updated 09/08/2021
- Taxonomy Code 207N00000X
- Entity Type Individual
- NPI Number 1831199884
Products in Payments
- Candin (Biological) $182,769
- Natroba (Drug) $2,500
- EUCRISA (Drug) $696.01
- Humira (Biological) $252.56
- TALTZ (Drug) $223.56
- Enbrel (Biological) $192.18
- COSENTYX (Biological) $173.20
- SKYRIZI (Biological) $172.75
- Erivedge (Biological) $120.93
- Tremfya (Drug) $114.15
- TREMFYA (Drug) $99.00
- ILUMYA (Biological) $92.91
- DUPIXENT (Biological) $85.26
- Rituxan (Biological) $76.00
- COSENTYX (Drug) $66.96
- DERMATITIS - DISEASE (Drug) $61.31
- ATOPIC DERMATITIS - DISEASE (Drug) $59.31
- DUPIXENT (Drug) $49.81
- DUPIXENT DUPILUMAB INJECTION (Biological) $34.61
- ILUMYA (tildrakizumab-asmn) injection (Biological) $33.02
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.